NEW IDSA cUTI GUIDELINE

A new Guideline for the treatment of cUTI just arrived.[1] First, we are glad that this somewhat mundane topic receives the attention it deserves.  UTIs are often downplayed as minor infections, but the cUTI variety should not be taken lightly.  Many patients still are admitted with life-threatening infections, so prompt Continue reading NEW IDSA cUTI GUIDELINE

A Renaissance for Old Drugs: Fosfomycin and Colistin

Fosfomycin Who would have thought that a drug that has been around since 1969 [2] could become eligible for QIDP status in 2015? Well, Zavante Therapeutics recently garnered the coveted QIDP designation for fosfomycin IV. This formulation has been available in Europe for a quite some time but not in the Continue reading A Renaissance for Old Drugs: Fosfomycin and Colistin